Guangdong Zhongsheng Pharmaceutical Co Ltd (002317) - Net Assets

Latest as of September 2025: CN¥4.13 Billion CNY ≈ $603.74 Million USD

Based on the latest financial reports, Guangdong Zhongsheng Pharmaceutical Co Ltd (002317) has net assets worth CN¥4.13 Billion CNY (≈ $603.74 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.17 Billion ≈ $756.15 Million USD) and total liabilities (CN¥1.04 Billion ≈ $152.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002317 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥4.13 Billion
% of Total Assets	79.84%
Annual Growth Rate	20.55%
5-Year Change	10.58%
10-Year Change	90.09%
Growth Volatility	147.93

Guangdong Zhongsheng Pharmaceutical Co Ltd - Net Assets Trend (2006–2024)

This chart illustrates how Guangdong Zhongsheng Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Guangdong Zhongsheng Pharmaceutical Co L worth.

Annual Net Assets for Guangdong Zhongsheng Pharmaceutical Co Ltd (2006–2024)

The table below shows the annual net assets of Guangdong Zhongsheng Pharmaceutical Co Ltd from 2006 to 2024. Also explore net asset momentum of Guangdong Zhongsheng Pharmaceutical Co L to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2024-12-31	CN¥4.01 Billion ≈ $586.81 Million	-11.39%
2023-12-31	CN¥4.53 Billion ≈ $662.25 Million	+18.58%
2022-12-31	CN¥3.82 Billion ≈ $558.47 Million	+7.87%
2021-12-31	CN¥3.54 Billion ≈ $517.74 Million	-2.44%
2020-12-31	CN¥3.63 Billion ≈ $530.67 Million	-12.29%
2019-12-31	CN¥4.13 Billion ≈ $605.00 Million	+4.65%
2018-12-31	CN¥3.95 Billion ≈ $578.14 Million	+5.91%
2017-12-31	CN¥3.73 Billion ≈ $545.87 Million	+8.94%
2016-12-31	CN¥3.42 Billion ≈ $501.07 Million	+62.32%
2015-12-31	CN¥2.11 Billion ≈ $308.69 Million	+11.10%
2014-12-31	CN¥1.90 Billion ≈ $277.85 Million	+8.94%
2013-12-31	CN¥1.74 Billion ≈ $255.05 Million	+9.85%
2012-12-31	CN¥1.59 Billion ≈ $232.18 Million	+7.41%
2011-12-31	CN¥1.48 Billion ≈ $216.16 Million	+6.53%
2010-12-31	CN¥1.39 Billion ≈ $202.91 Million	+7.07%
2009-12-31	CN¥1.30 Billion ≈ $189.52 Million	+651.26%
2008-12-31	CN¥172.40 Million ≈ $25.23 Million	+32.04%
2007-12-31	CN¥130.56 Million ≈ $19.11 Million	-5.88%
2006-12-31	CN¥138.72 Million ≈ $20.30 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Guangdong Zhongsheng Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1370.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥915.41 Million	23.38%
Common Stock	CN¥851.56 Million	21.75%
Other Components	CN¥2.15 Billion	54.86%
Total Equity	CN¥3.91 Billion	100.00%

Guangdong Zhongsheng Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Guangdong Zhongsheng Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Brederode SA BR:BREB	$3.01 Billion
AIR CHINA LTD H ADR/20 F:AD2B	$3.01 Billion
Becle S.A.B. de C.V MX:CUERVO	$3.01 Billion
National Storage REIT AU:NSR	$3.02 Billion
Virbac SA PA:VIRP	$3.01 Billion
Vidrala SA MC:VID	$3.01 Billion
Red Rock Resorts Inc NASDAQ:RRR	$3.01 Billion
Schneider National Inc NYSE:SNDR	$3.01 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Guangdong Zhongsheng Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 4,356,304,632 to 3,914,773,066, a change of -441,531,566 (-10.1%).
Net loss of 299,157,112 reduced equity.
Dividend payments of 170,953,595 reduced retained earnings.
Share repurchases of 8,934,120 reduced equity.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥-299.16 Million	-7.64%
Dividends Paid	CN¥170.95 Million	-4.37%
Share Repurchases	CN¥8.93 Million	-0.23%
Other Changes	CN¥37.51 Million	+0.96%
Total Change	CN¥-	-10.14%

Book Value vs Market Value Analysis

This analysis compares Guangdong Zhongsheng Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 5.14x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 102.11x to 5.14x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-12-31	CN¥0.24	CN¥24.22	x
2007-12-31	CN¥0.22	CN¥24.22	x
2008-12-31	CN¥0.32	CN¥24.22	x
2009-12-31	CN¥2.41	CN¥24.22	x
2010-12-31	CN¥1.92	CN¥24.22	x
2011-12-31	CN¥2.06	CN¥24.22	x
2012-12-31	CN¥2.19	CN¥24.22	x
2013-12-31	CN¥2.33	CN¥24.22	x
2014-12-31	CN¥2.55	CN¥24.22	x
2015-12-31	CN¥2.78	CN¥24.22	x
2016-12-31	CN¥4.42	CN¥24.22	x
2017-12-31	CN¥4.59	CN¥24.22	x
2018-12-31	CN¥4.75	CN¥24.22	x
2019-12-31	CN¥5.06	CN¥24.22	x
2020-12-31	CN¥4.39	CN¥24.22	x
2021-12-31	CN¥4.36	CN¥24.22	x
2022-12-31	CN¥4.60	CN¥24.22	x
2023-12-31	CN¥5.29	CN¥24.22	x
2024-12-31	CN¥4.71	CN¥24.22	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Guangdong Zhongsheng Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -7.64%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -12.12%
• Asset Turnover: 0.44x
• Equity Multiplier: 1.42x
Recent ROE (-7.64%) is below the historical average (11.87%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	24.74%	9.75%	1.12x	2.26x	CN¥18.99 Million
2007	35.51%	10.45%	1.36x	2.50x	CN¥30.36 Million
2008	43.15%	15.36%	1.54x	1.83x	CN¥57.14 Million
2009	7.75%	18.19%	0.39x	1.08x	CN¥-29.16 Million
2010	9.48%	20.53%	0.43x	1.07x	CN¥-7.16 Million
2011	10.19%	20.29%	0.47x	1.06x	CN¥2.82 Million
2012	11.44%	20.48%	0.51x	1.09x	CN¥22.84 Million
2013	11.14%	17.22%	0.55x	1.18x	CN¥19.26 Million
2014	12.15%	17.16%	0.57x	1.25x	CN¥39.68 Million
2015	14.40%	18.81%	0.47x	1.62x	CN¥90.60 Million
2016	12.21%	24.48%	0.40x	1.24x	CN¥74.90 Million
2017	11.33%	21.39%	0.40x	1.31x	CN¥49.41 Million
2018	11.16%	18.45%	0.45x	1.34x	CN¥45.35 Million
2019	7.81%	12.55%	0.46x	1.35x	CN¥-88.86 Million
2020	-12.10%	-22.50%	0.40x	1.35x	CN¥-779.10 Million
2021	7.99%	11.43%	0.50x	1.41x	CN¥-69.93 Million
2022	8.70%	12.03%	0.46x	1.56x	CN¥-48.22 Million
2023	6.04%	10.08%	0.40x	1.48x	CN¥-172.36 Million
2024	-7.64%	-12.12%	0.44x	1.42x	CN¥-690.63 Million

Industry Comparison

This section compares Guangdong Zhongsheng Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $8,448,219,723
Average return on equity (ROE) among peers: 10.70%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Guangdong Zhongsheng Pharmaceutical Co Ltd (002317)	CN¥4.13 Billion	24.74%	0.25x	$3.01 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$2.14 Billion	22.15%	4.96x	$585.22 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.15 Billion	3.98%	1.16x	$407.31 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$897.61 Million	10.79%	0.14x	$4.27 Billion
Livzon Pharmaceutical Group Inc (000513)	$14.94 Billion	12.78%	0.66x	$2.26 Billion
Wedge Industrial Co Ltd (000534)	$552.92 Million	0.39%	0.01x	$1.78 Billion
Yunnan Baiyao Group Co Ltd (000538)	$38.10 Billion	10.98%	0.30x	$13.33 Billion
Hainan Haiyao Co Ltd (000566)	$5.63 Billion	2.92%	0.71x	$875.19 Million
Tus Pharmaceutical Group Co Ltd (000590)	$141.91 Million	11.01%	0.32x	$311.17 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$2.05 Billion	23.18%	1.96x	$973.03 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$18.87 Billion	8.83%	0.08x	$3.07 Billion

About Guangdong Zhongsheng Pharmaceutical Co Ltd

SHE:002317 China Drug Manufacturers - Specialty & Generic

Market Cap

$3.01 Billion

CN¥20.59 Billion CNY

Market Cap Rank

#4934 Global

#848 in China

Share Price

CN¥24.22

Change (1 day)

-1.70%

52-Week Range

CN¥16.56 - CN¥33.29

All Time High

CN¥38.56